Brian K. Fiske, PhD

Job title:

Associate Director, Team Leader, Research Programs

Organization:

Michael J. Fox Foundation for Parkinson's Research (MJFF)

Bio:

Dr. Brian Fiske earned his undergraduate degree in cellular and molecular biology from Texas A&M University and his PhD in Neuroscience from the University of Virginia, where his research interests focused on the role of sensory experience in early postnatal brain development. After a brief postdoctoral fellowship at Columbia University (and a move to the big city), Brian found a new calling as an editor for the scientific journal Nature Neuroscience, where he helped evaluate and review a wide range of cutting-edge scientific research. In 2004, he moved from publishing science to funding it: he now works at The Michael J. Fox Foundation for Parkinson’s Research helping to support development of new treatments and ultimately a cure for Parkinson’s disease.

Technology:

PD Guide Terms:

Pathogenic Mechanisms

Compensatory & Neuronal Health Mechanisms

Therapeutic Development

Contributions:

Published Contributions:

Implications of FDOPA PET signal changes in early PD?

response to: A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.

9 Apr 2009 04:56 PM EST

Understanding the natural progression of Parkinson's disease is critical for clinical trials and determining best treatment options for people at various stages of disease course. Bruck and ...

Utility of Diffusion Tensor Imaging as diagnostic marker for PD?

response to: High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

9 Apr 2009 05:32 PM EST

Vaillancourt and colleagues provide evidence that diffusion tensor imaging has near perfect ability to distinguish early, untreated PD cases from healthy individuals. If true, DTI could provide a ...

Promise of mGluR5 receptor targeting for PD-related dyskinesias?

response to: Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalling.

10 Apr 2009 05:51 PM EST

Rylander and colleagues provide supportive data that the mGluR5 receptor antagonist MTEP is effective in reducing dyskinesias in a rodent model of PD. Targeting other glutamate receptors, including ...

Workgroups: